ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nacubactam

Also written as “RO7079901”, “co-administration of cefepime and nacubactam” and “co-administration of aztreonam and nacubactam”.

Its studies are mostly in Intraabdominal Infections · Pyelonephritis · Urinary Tract Infections · Gram-Negative Bacterial Infections · Renal Insufficiency, led by 2 companies.

Drug pageNacubactam: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 21, 20167 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only40 open or runningphase 1since Nov 21, 2016Nov 21, 2016none ahead
Meiji Seika Pharma30 open or runningphase 3since Mar 2, 2023May 7, 2014none ahead
  • Named in fosun pharma’s own pipeline as OP0595 (beta-lactamase inhibitor), phase 3, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Meiji Seika Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 7, 2014First study: phase 1 study in Bacterial InfectionsFirst studyNCT02134834 · 40 enrolled · Australia
  2. Jun 9, 2016Named nacubactamINNProposed as its International Nonproprietary Name in WHO's List 115 · before, RO7079901, OP0595
  3. Mar 2, 2023Phase 3 study in Complicated Urinary Tract InfectionNCT05905055 · 126 enrolled · China, Croatia, Czechia and more
  4. Apr 25, 2023Phase 3 study in Complicated Urinary Tract InfectionNCT05887908 · 614 enrolled · Bulgaria, China, Czechia and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Meiji Seika Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05887908Complicated Urinary Tract Infection · Bulgaria, China, Czechia and more3CompletedNov 22, 2024614
NCT05905055Complicated Urinary Tract Infection · China, Croatia, Czechia and more3CompletedSep 1, 2025126
NCT02134834Bacterial Infections · Australia1CompletedAug 201440

How it is read

Names in the registry

  • “RO7079901”, 3 entries
  • “co-administration of cefepime and nacubactam”, 2 entries
  • “co-administration of aztreonam and nacubactam”, 2 entries
  • “nacubactam”, 1 entry
  • “OP0595”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.